Side-by-side comparison of AI visibility scores, market position, and capabilities
San Jose EDA software and hardware emulation (NASDAQ: CDNS) $4.64B FY2024 revenue (+14%); Virtuoso/Genus/Innovus chip design platform, Palladium Z2 emulator, AI design tools competing with Synopsys and Siemens EDA.
Cadence Design Systems, Inc. is a San Jose, California-based electronic design automation (EDA) software and hardware company — publicly traded on the NASDAQ (NASDAQ: CDNS) as an S&P 500 Information Technology component — providing software tools, hardware emulation systems, and IP (intellectual property) used by semiconductor and electronics companies to design and verify chips, printed circuit boards, and electronic systems through approximately 10,000 employees worldwide. In fiscal year 2024, Cadence reported revenues of $4.64 billion (+14% year-over-year) with subscription-based EDA software generating 80%+ recurring revenue as chip designers use Cadence's Virtuoso (analog/mixed-signal IC design), Genus (logic synthesis), Innovus (place-and-route for digital chips), Tempus (static timing analysis), and Palladium/Protium hardware emulation products throughout the entire chip design workflow. CEO Anirudh Devgan has executed Cadence's "Intelligent System Design" strategy: expanding from pure EDA software tools into hardware system design (Clarity electromagnetic field solver for package and PCB signal integrity), computational fluid dynamics (Omnis-Flow for electronic cooling analysis), and AI-driven chip design (Cadence AI tools — Genus AI, Innovus AI — using machine learning to automatically optimize chip synthesis and place-and-route to achieve better power, performance, and area tradeoffs than human-guided optimization). Cadence's computational software expansion (Fidelity+ CFD, Clarity 3D, Celsius electro-thermal analysis) adds a new revenue stream from automotive, aerospace, and electronics companies performing fluid simulation, thermal analysis, and electromagnetic analysis alongside chip design workflows.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.